MAP2K7 and gastric cancer: As loss or reduction of Lnc21q22.11 expression activated MEK/ERK signaling pathway, the sensitivity of GC cells with or without Lnc21q22.11 expression to selumetinib, a MEK inhibitor, was assessed by MTT assay.